Cancer types that are likely to be most susceptible to treatment with DT2216 include: (1) those in which TI-Tregs are critical for immune regulation and cancer progression; and (2) those that rely on BCL-XL for survival and in which high BCL-XL levels and poor outcome are positively correlated. This evidence concerns the gene BCL2L1 and cancer.